Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,352

Document Document Title
WO/2018/152592A1
The present disclosure relates to methods and products for reducing adhesions. In certain embodiments, the present disclosure provides a method of reducing adhesions in a subject, the method comprising exposing a region in the subject su...  
WO/2018/144637A1
Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol...  
WO/2018/143115A1
Provided is a bioabsorbable stent that has adequate strength, is highly robust and flexible, and has excellent expandability. This bioabsorbable stent is characterized in that a plurality of first tubular units in which a plurality of su...  
WO/2018/134621A1
A composition for aiding the removal of polyps, in the form of a submucosal injectable formulation, comprising one or more salts of hyaluronic acid, saline solution and indigo carmine, but not including a substance exhibiting an angioton...  
WO/2018/115800A1
The invention relates to a pharmaceutical composition comprising between 10 and 30 g/L fibrinogen, between 10 and 300 mM arginine, and between 10 and 300 mM glutamate. In addition, the composition has a pH of between 6 and 8.  
WO/2018/094470A1
The present invention relates generally to methods and compositions for reducing the side effects of neuroexcitation associated with general anaesthetic agents by using cannabinoid- 1 receptor antagonists (CB IR) or inverse agonists. The...  
WO/2018/062464A1
Provided is an anti-conglutination material that has an operability that allows reliable attachment thereof to biological tissue and in which tissue adhesiveness and biodegradability are improved. The anti-conglutination material has a w...  
WO/2018/043731A1
The present invention relates to an anti-adhesion agent containing an emulsion composition that contains a lipid compound represented by general formula (I), an oil component and a surfactant in an aqueous phase. (In the formula, each of...  
WO/2018/019244A1
The present invention relates to salts of 2,6-dimethylpyrimidone derivative and uses of the salts. The present invention also relates to a pharmaceutical composition comprising the salts or a combination thereof, and uses of the salts or...  
WO/2018/014894A1
The invention relates to a medicament which a.) contains or even consists of carboxymethylated starch and/or b.) contains or even consists of epichlorohydrin-modified starch for the treatment of anastomoses.  
WO/2017/153889A1
The present invention relates to a method of accelerating stem cell engraftement in a patient in need of hematopoietic stem cell transplantation.  
WO/2017/147058A1
Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.  
WO/2017/130802A1
The present invention addresses the problem of providing a cell sheet composition for healing or preventing discharge from a wounded region of a luminal organ. The present invention also addresses the problem of providing a method in whi...  
WO/2017/123653A1
Disclosed herein are pharmaceutical compositions useful for the treatment and prevention of adhesions and ileus.  
WO/2017/114902A1
There is provided a method of decellularizing adipose tissue comprising the steps of: a) Laminating the adipose tissue;b) Treating the adipose tissue resulting from step a) with a lipoprotein lipase at 32-42 degrees Celsius and at a conc...  
WO/2017/082840A1
The present invention relates to the use of a zeolite as a chemical agent with additional cytotoxic effects used in pleurodesis in the cases of liquid accumulation (pleural effusion) or air accumulation (pneumothorax) in the pleural cavi...  
WO/2017/078563A1
The present invention relates to medical biotechnology and cell technology. Proposed is a method for isolating stromal vascular fraction of adipose tissue, which includes: decantation of a lipoaspirate; delicate washing of the lipoaspira...  
WO/2017/078563A8
The present invention relates to medical biotechnology and cell technology. Proposed is a method for isolating stromal vascular fraction of adipose tissue, which includes: decantation of a lipoaspirate; delicate washing of the lipoaspira...  
WO/2017/053733A1
A hydrogel delivery composition, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid stat...  
WO/2017/013120A1
Peritoneal therapeutic fluid comprising one or more of a biocompatibility enhancing agent (BCA) that is selected from the group consisting of a polyphenolic compound, a metabolite of a polyphenolic compound which is obtained by metaboliz...  
WO/2016/204266A1
The purpose of the present invention is to provide a polymer film which can conform to movements of the living body or to fine ruggedness and further has excellent adhesion to biotissues. The present invention provides a polymer film whi...  
WO/2016/191820A1
Disclosed in some forms is a process of limiting the impact of surgery on a nerve, the process comprising applying a therapeutic substance to the nerve during surgery. In some aspects, disclosed is a formulation for reducing nerve trauma...  
WO/2016/184591A1
The present invention relates to a method of administering a composition comprising n-3 PUFAs to a patient who has received, or who is scheduled to receive, a renal transplant. Particularly, the invention provides a method to increase th...  
WO/2016/175290A1
Provided is a composition that can be used for a preservative medium or a perfusate of internal organs. Otherwise, provided is a composition that extends the life of normal cells, and/or a composition that suppresses the life of cancer c...  
WO/2016/167229A1
Provided is a method for producing a cross-linked product of carboxymethyl group-containing modified hyaluronic acid and/or a salt of the same, having excellent thermal stability, enzymolysis resistance and water-swelling characteristics...  
WO/2016/136886A1
Provided is a medical/cosmetic material in which characteristics inherent in polyanionic polysaccharides, which are starting materials, are maintained, that is highly safe because there is no need to use chemical cross-linking agents dur...  
WO/2016/114355A1
The present invention provides a composition for preventing adhesion using a combination of (a) a monovalent metal salt of low-endotoxin alginic acid, (b) carboxymethylcellulose or a pharmacologically acceptable salt thereof, and (c) cel...  
WO/2016/094535A1
Methods and hydrogels for preventing or reducing cellular adhesion and protein adsorption to a tissue (e.g. cardiac tissue) are disclosed. The hydrogels generally include at least two component polymers, a first polymer including an amin...  
WO/2016/069897A1
Cell-containing implants populated with endothelial cells rescue liver donor and recipient endothelium and parenchyma from ischemic injury after major hepatectomy and engraftment. The inventions disclosed herein highlight the discovery t...  
WO/2016/061147A1
This disclosure provides a method for improving maturation of an arteriovenous fistula (AVF) in a patient in need of hemodialysis, which method entails applying a solution to the internal wall of a lumen of an AVF; and restoring or initi...  
WO/2016/055160A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2016/030278A1
The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme containing an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert s...  
WO/2015/197098A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2015/197194A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2015/198245A1
The invention provides compositions for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and methods of using the compositions. The compositions are vitr...  
WO/2015/184380A1
A treatment for reducing brain or other injury that can be used before, during, or after a surgical treatment or other injury to the brain to decrease or prevent subsequent damage. Injury to the brain during surgery or from other trauma ...  
WO/2015/184380A8
A treatment for reducing brain or other injury that can be used before, during, or after a surgical treatment or other injury to the brain to decrease or prevent subsequent damage. Injury to the brain during surgery or from other trauma ...  
WO/2015/133559A1
 Hyaluronic acid modified by sphingosine-1-phosphoric acid, and a pharmaceutical containing this hyaluronic acid as an active ingredient, the pharmaceutical making it possible to reduce liver damage due to hypoxia/reoxygenation by prot...  
WO/2015/126917A3
Methods are provided that include applying to a surgical field in the patient following a lymphadenectomy or other procedure in which a lymph node or lymphatic vessel is dissected, a bioresorbable and biocompatible material in an amount ...  
WO/2015/125904A1
[Problem] To provide an anti-human PAI-1 antibody for prevention and treatment of pulmonary fibrosis by binding to active human PAI-1 and inhibiting effects mediated by active human PAI-1. [Solution] The inventors studied anti-PAI-1 anti...  
WO/2015/090232A1
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also pro...  
WO/2015/080671A1
The present invention relates to the use of peptides, peptoids and/or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydro...  
WO/2015/060430A1
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with mu...  
WO/2015/029892A1
 A method for manufacturing a water-insoluble molded article having a step for treating a starting material molded article composed of a water-soluble salt of a polyanionic polysaccharide using a treatment liquid containing an acid anh...  
WO/2015/012730A1
A method is proposed for making biodegradable membranes intended for preventing development of an adhesive disease following open heart surgery. The production of the biodegradable membranes is carried out on the basis of a polymer co...  
WO/2015/006831A9
The invention relates to compositions and methods for reducing at least one of inflammation, coagulation, adhesions and scar formation in an injured subject or inducing a hypotensive state or a iow pain or analgesic state in an injured s...  
WO/2015/006829A1
The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of inf...  
WO/2015/006831A1
The invention relates to compositions and methods for reducing at least one of inflammation, coagulation, adhesions and scar formation in an injured subject or inducing a hypotensive state or a iow pain or analgesic state in an injured s...  
WO/2014/206563A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2014/206427A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  

Matches 1 - 50 out of 2,352